Elizabeth McDonald, MD, PhD, on GLP-1 Agonists and Breast Cancer Incidence

June 08, 2026 By The ASCO Post Staff

Elizabeth McDonald, MD, PhD, of the University of Pennsylvania, discusses results from a retrospective cohort study that showed that the use of GLP-1 treatment was associated with a significantly lower incidence of breast cancer, after accounting for age, race, ethnicity, BMI, breast density, and type 2 diabetes status (Abstract 10506).

Related Content